Clinical Trial Update: A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

View source ↗

Summary

A real-world French study evaluating how durvalumab is used and its effectiveness as first-line therapy for extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Carcinoma | Status: ACTIVE_NOT_RECRUITING